Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence

References

• Singh OP, Singh B, Chakravarty J, et al. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016 Mar 8;5:19.
   PubMed Web of Science ®Google Scholar
• Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671.
   PubMed Web of Science ®Google Scholar
• Postigo JA. Leishmaniasis in the World Health Organization Eastern Mediterranean region. Int J Antimicrob Agents. 2010;36(Suppl 1):S62–S65.
   PubMed Web of Science ®Google Scholar
• Boelaert M, Meheus F, Sanchez A, et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009;14:639–644.
   PubMed Web of Science ®Google Scholar
• Singh OP, Hasker E, Boelaert M, et al. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016 Dec;16(12):e304–e309.
   PubMedGoogle Scholar
• Ostyn B, Vanlerberghe V, Picado A, et al. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health. 2008;13:1073–1085.
   PubMed Web of Science ®Google Scholar
• Control of the leishmaniases. World Health Organisation Techechnical Report Ser. 2011. Available from: http://apps.who.int/iris/handle/10665/44412
   Google Scholar
• Accelerated Plan for Kala-azar Elimination-2017. [cited 2018 Sep 13]. Available from: http://nvbdcp.gov.in/Doc/Accelerated-Plan-Kala-azar1-Feb2017.pdf
   Google Scholar
• WHO-TDR. Research to support the elimination of visceral leishmaniasis. [cited 2018 Sep 13]. Available from: http://www.who.int/tdr/publications/about-tdr/annual-reports/bl10-annual-report/en/2010
   Google Scholar
• WHO. Global health observatory data repository. [cited 2017 Sep 15]. Available from: http://apps.who.int/gho/data/node.main.NTDLEISHVNUM?lang=en
   Google Scholar
• Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis. 2014;8:e3053.
   PubMed Web of Science ®Google Scholar
• Molina R, Lohse JM, Pulido F, et al. Infection of sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus. Am J Trop Med Hyg. 1999;60:51–53.
   PubMed Web of Science ®Google Scholar
• Stauch A, Sarkar RR, Picado A, et al. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis. 2011;5:e1405.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh OP. Molecular diagnosis of visceral leishmaniasis. Mol Diagn Ther. 2018;22:443–457.
   PubMed Web of Science ®Google Scholar
• Ostyn B, Gidwani K, Khanal B, et al. Incidence of symptomatic and asymptomatic leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis. 2011;5:e1284.
   PubMed Web of Science ®Google Scholar
• Singh OP, Hasker E, Sacks D, et al. Asymptomatic leishmania infection: a new challenge for leishmania control. Clin Infect Dis. 2014;58:1424–1429.
   PubMed Web of Science ®Google Scholar
• Das S, Matlashewski G, Bhunia GS, et al. Asymptomatic Leishmania infections in northern India: a threat for the elimination programme? Trans R Soc Trop Med Hyg. 2014;108:679–684.
   PubMed Web of Science ®Google Scholar
• Hasker E, Kansal S, Malaviya P, et al. Latent infection with Leishmania donovani in highly endemic villages in Bihar, India. PLoS Negl Trop Dis. 2013;7:e2053.
   PubMed Web of Science ®Google Scholar
• Hasker E, Malaviya P, Gidwani K, et al. Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl Trop Dis. 2014;8:e2657.
   PubMed Web of Science ®Google Scholar
• Singh OP, Gidwani K, Kumar R, et al. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol. 2012;19:961–966.
   PubMed Web of Science ®Google Scholar
• le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol. 1999;37:1953–1957.
   PubMed Web of Science ®Google Scholar
• Singh OP, Sundar S. Whole blood assay and visceral leishmaniasis: challenges and promises. Immunobiology. 2014;219:323–328.
   PubMed Web of Science ®Google Scholar
• Haldar A, Sen P, Roy S Use of antimony in the treatment of leishmaniasis: current status and future directions. Molecular Biology International 2011; 2011. p. 1–23.
   Google Scholar
• Boelaert M, Criel B, Leeuwenburg J, et al. Visceral leishmaniasis control: a public health perspective. Trans R Soc Trop Med Hyg. 2000;94:465–471.
   PubMed Web of Science ®Google Scholar
• Croft S, Sundar S, Fairlamb A. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111–126.
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31:1104–1107.
   PubMed Web of Science ®Google Scholar
• Rijal S, Bhandari S, Koirala S, et al. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal. Trans R Soc Trop Med Hyg. 2010;104:225–229.
   PubMed Web of Science ®Google Scholar
• Duncan R, Gannavaram S, Dey R, et al. Identification and characterization of genes involved in leishmania pathogenesis: the potential for drug target selection. Molecular Biology International 2011; 2011. p. 1–10.
   Google Scholar
• Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013;14:53–63.
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha P, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377:477–486.
   PubMed Web of Science ®Google Scholar
• Matlashewski G, Arana B, Kroeger A, et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis. 2011;11:322–325.
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014 Aug 15;59(4):552–555. Epub 2014 May 10.
   PubMed Web of Science ®Google Scholar
• Hirve S, Kroeger A, Matlashewski G, et al. Towards elimination of visceral leishmaniasis in the Indian subcontinent-translating research to practice to public health. PLoS Negl Trop Dis. 2017 Oct 12;11(10):e0005889.
   PubMed Web of Science ®Google Scholar
• Le Rutte EA, Coffeng LE, Bontje DM, et al. Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models. Parasites Vectors. 2016 Jan 19;9:24.
   PubMed Web of Science ®Google Scholar
• Medley GF, Hollingsworth TD, Olliaro PL, et al. Health-seeking behaviour, diagnostics and transmission dynamics in the control of visceral leishmaniasis in the Indian subcontinent. Nature. 2015 Dec 3;528(7580):S102–S108.
   PubMed Web of Science ®Google Scholar
• Tiwary P, Singh S, Kushwaha AK, et al. Establishing, expanding, and certifying a closed colony of Phlebotomus argentipes (Diptera: Psychodidae) for Xenodiagnostic Studies at the Kala Azar Medical Research Center, Muzaffarpur, Bihar, India. J Med Entomol. 2017;54(5):1129–1139.
   PubMed Web of Science ®Google Scholar
• Alexander B, Jaramillo C, Usma MC, et al. An attempt to control Phlebotomine sand flies (Diptera: Psychodidae) by residual spraying with deltamethrin in a Colombian village. Mem Inst Oswaldo Cruz. 1995;90:421–424.
   PubMed Web of Science ®Google Scholar
• Dhiman RC, Pahwa S, Dhillon GP, et al. Climate change and threat of vector-borne diseases in India: are we prepared? Parasitol Res. 2010;106:763–773.
   PubMed Web of Science ®Google Scholar
• Poché DM, Garlapati RB, Mukherjee S, et al. Bionomics of Phlebotomus argentipes in villages in Bihar, India with insights into efficacy of IRS-based control measures. PLoS Negl Trop Dis. 2018;12:e0006168.
   PubMed Web of Science ®Google Scholar
• Coleman M, Foster GM, Deb R, et al. DDT-based indoor residual spraying suboptimal for visceral leishmaniasis elimination in India. Proc Natl Acad Sci USA. 2015 Jul 14; 112(28):8573–8578.
   PubMed Web of Science ®Google Scholar
• Alexander B, Maroli M. Control of phlebotomine sandflies. Med Vet Entomol. 2003;17:1–18.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Kumar V, Mondal D, et al. Implication of vector charecteristics of Phlebotomous argentipes in the kala-azar elimination program in the Indian sub-continent. Pathogen Global Health. 2016;110(3):87–96.
   PubMed Web of Science ®Google Scholar
• Poche D, Garlapati R, Ingenloff K, et al. Bionomics of phlebotomine sand flies from three villages in Bihar, India. J Vector Ecol. 2011;36(Suppl 1):S106–S117.
   PubMedGoogle Scholar
• Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ. 1992;70:341–346.
   PubMed Web of Science ®Google Scholar
• van Griensven J. Visceral leishmaniasis and HIV coinfection in Bihar, India: a wake-up call? Clin Infect Dis. 2014 Aug 15;59(4):556–558.
   PubMed Web of Science ®Google Scholar
• Raman VS, Duthie MS, Fox CB, et al. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol. 2012;3:144–147.
   PubMed Web of Science ®Google Scholar
• Kumar R, Engwerda C. Vaccines to prevent leishmaniasis. Clin Transl Immunol. 2014;3(3):e13.
   PubMedGoogle Scholar
• Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol. 2014;5:296.
   PubMed Web of Science ®Google Scholar
• Chakravarty J, Kumar S, Trivedi S, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011;29:3531–3537.
   PubMed Web of Science ®Google Scholar
• Ostyn B, Uranw S, Bhattarai NR, et al. Transmission of leishmania donovani in the Hills of Eastern Nepal, an outbreak investigation in Okhaldhunga and Bhojpur districts. PLoS Negl Trop Dis. 2015;9(8):e0003966.
   PubMed Web of Science ®Google Scholar
• Le Rutte EA, Chapman LAC, Coffeng LE, et al. Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models. Epidemics. 2017;18:67–80.
   PubMed Web of Science ®Google Scholar